Journal of International Oncology››2013,Vol. 40››Issue (1): 50-53.

Previous ArticlesNext Articles

Endostatin in the treatment of non-small-cell lung cancer

ZHANG Lei, XU Jian-Yu, XU Xiang-Ying

  1. Department of RadiationOncology,the Third Affiliated Hospital of Harbin Medical University , Harbin 150081, China

  • Online:2013-01-08Published:2013-01-15
  • Contact:XU Xiang-Ying,E-mail:xuxxyy@sohu.com E-mail:xuxxyy@sohu.com

Abstract:Endostatin is a novel anti-angiogenic drug which through multiple pathway inhibits vascular endothelial growth factor expression, to achieve the purpose of the inhibition of tumor angiogenesis. The drug in the treatment of non-small-cell lung cancer in pre-clinical study and clinical application show that: used alone have anti-tumor effect; combined with radiotherapy and chemotherapy can obtain short-term curative effect, and does not increase treatment related toxicity. The adverse effect of the drug is mild and can be well tolerated.

Key words:Endostratins,Carcinoma, non-small-cell lung,Radiotherapy,Drug therapy